MDMantana Dhanachai

Mantana Dhanachai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mantana Dhanachai has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Boonchu Kulapraditharom

    ENT Department, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand

    1 shared publication
  • Ekaphop Sirachainan

    Mahidol University

    1 shared publication
  • Jiraporn Laothamatas

    Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand

    1 shared publication
  • Ladawan Narkwong

    Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand

    1 shared publication
  • Pornpan Yongvithisatid

    Radiosurgery Center, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand

    1 shared publication
  • Puangtong Kraiphibul

    Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand

    1 shared publication

Latest Publications

  • Open Access

    Fractionated stereotactic radiotherapy in residual or recurrent nasopharyngeal carcinoma

    by Mantana Dhanachai, Puangtong Kraiphibul, Somjai Dangprasert, Putipun Puataweepong, Ladawan Narkwong, Jiraporn Laothamatas, Boonchu Kulapraditharom, Ekaphop Sirachainan, Pornpan Yongvithisatid

    The aim of this study was to evaluate results of fractionated stereotactic radiotherapy (FSRT) in patients with residual or recurrent nasopharyngeal carcinoma (NPC) in terms of local progression-free (LPFS) and overall survival (OS) rate and complications after treatment. There were 32 residual or recurrent NPC patients treated with FSRT using linac-based radiosurgery system. Time from the previous radiotherapy to FSRT was 1–165 months (median, 15). Two patients were treated for the second and one for the third recurrence. Thirteen patients (40.6%) also received chemotherapy with FSRT. Tumor volume ranged from 6.2–215 cc (median, 44.4). Average FSRT dose was 17–59.4 Gy (median, 34.6) in 4–25 fractions (median,6) in 1–5.5 weeks (median, 3). Median follow-up time was 25.5(3–67) months. LPFS rate at 1 and 3 years after FSRT was 67.8% and 37.9%. OS rate at 1 and 3 years was 89.7% and 71.2%. If all patients who had tumor progression with no further follow-up were assumed dead, the OS rate at 1 and 3 years would be 75.0% and 37.9%. Univariate analysis showed better local tumor control in patients with tumor volume ≤100 cc (p=0.04) or in those without chemotherapy (p=0.0005). Only chemotherapy retained significance in multivariate analysis (hazard ratio 5.47, 95%CI 1.86–16.04). Eight patients (25%) had complications after FSRT, all grade 2–3 except 1 grade 4 with complete recovery.